FLUOPATCH: Fluorescence Imaging of the Parathyroid Glands of Children

Sponsor
Amsterdam University Medical Centers (UMC), Location Academic Medical Center (AMC) (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05917067
Collaborator
Stichting Kinderen Kankervrij (KiKa) (Other)
20
3
13
6.7
0.5

Study Details

Study Description

Brief Summary

The aim of this study is to develop a standardized and user-independent imaging workflow model for autofluorescence and quantified fluorescence angiography with Indocyanine Green (ICG) of the parathyroid glands of children. For this purpose, all pediatric patients will undergo thyroid surgery with the use of autofluorescence and quantified ICG-fluorescence.

This study could be the first step in reducing the rate of postoperative hypocalcemia in children, by using fluorescence angiography during pediatric thyroid surgery.

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: Fluorescence imaging of the parathyroid glands of children

Detailed Description

Background:

Children with thyroid cancer have excellent survival rates. However, postoperative hypocalcemia, due to inadvertent excision of the parathyroid glands or damage to their vasculature during thyroid surgery, is a severe complication which occurs in 24% - 67% of the children with thyroid cancer and causes lifelong reduced quality of life and increased morbidity rates. In adults, intraoperative identification of the parathyroid glands with autofluorescence and assessment of their perfusion using quantified ICG-fluorescence angiography has shown to reduce postoperative hypocalcemia. However, in children no studies regarding quantified fluorescence of the parathyroid glands have been conducted. There is a clear need for surgical techniques to identify and preserve the parathyroid glands during thyroid surgery in children.

Therefore, the aim of this study is to develop a standardized imaging workflow model for autofluorescence and quantified ICG-angiography of the parathyroid glands in children. This workflow model can be the first step in reducing the rate of postoperative hypocalcemia in children.

Study design:

This will be a prospective, observational, multicenter, feasibility study. The aim is to generate the patterns of intraoperative autofluorescence and quantified ICG-fluorescence angiography of the parathyroid glands in children, resulting in a user-independent, standardized imaging workflow model for autofluorescence and quantified ICG-angiography of the parathyroid glands of children.

Study Design

Study Type:
Observational
Anticipated Enrollment :
20 participants
Observational Model:
Other
Time Perspective:
Prospective
Official Title:
Fluorescence Imaging for the Detection and Perfusion of the Parathyroid Glands of Children
Anticipated Study Start Date :
Aug 1, 2023
Anticipated Primary Completion Date :
Aug 1, 2024
Anticipated Study Completion Date :
Sep 1, 2024

Arms and Interventions

Arm Intervention/Treatment
Children (<18 years) that will undergo total thyroidectomy for any indication

Diagnostic Test: Fluorescence imaging of the parathyroid glands of children
Patients that participate in this study will always receive standard care. For the purpose of this study, the camera settings (i.e. camera distance to the operating field, switching of OR-lights, and angle of the camera on the operating field) and ICG-protocol (i.e. dose, injection speed) will be standardized among the participating centers in order to generate an homogeneous data set for quantification of the fluorescence signal intensity.

Outcome Measures

Primary Outcome Measures

  1. Number and location of autofluorescent parathyroid glands [During thyroid surgery]

    Number and location of autofluorescent parathyroid glands

  2. Quantification of the fluorescent signal of ICG [During thyroid surgery]

    Quantification of the fluorescent signal of ICG

  3. Postoperative hypocalcemia [Postoperative day 1-3 and first out-patient clinic visit (between day 1 and day 10 postoperative)]

    Postoperative hypocalcemia

Other Outcome Measures

  1. Postoperative calcium supplementation [Postoperative day 1-3 and first out-patient clinic visit (between day 1 and day 10 postoperative)]

    Need for (extra) postoperative calcium supplementation

  2. Total duration of the operation [Day of the operation]

    Total duration of the operation in minutes

  3. (postoperative) complications, following the Clavien-Dindo classification [During thyroid surgery and day 1-3 till and first out-patient clinic visit (between day 1 and day 10 postoperative)]

    Any (postoperative) complications, following the Clavien-Dindo classification

  4. Need for autotransplantation of the parathyroid glands [During thyroid surgery]

    Need for autotransplantation of the parathyroid glands by visual assessment (non-fluorescence) of the surgeon

Eligibility Criteria

Criteria

Ages Eligible for Study:
N/A to 18 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  1. Patients <18 years

  2. Patients undergoing total thyroidectomy (for any indication)

  3. Patients undergoing lobectomy for the suspicion of a malignancy, with a subsequent completion thyroidectomy

  4. Written informed consent (from parents/caregivers, patients or both, see chapter 6.0)

Exclusion Criteria:
  1. Patients with preoperative hypo - or hypercalcemia, treated for hypo- or hypercalcemia, (chronic) renal disease, kidney transplantation or any disorder that requires calcium supplementation (other than standard preoperative calcium supplementation for a total thyroidectomy).

  2. Patients with known allergy to ICG or iodinated contrast

  3. Pregnancy or breastfeeding

  4. Patients with severe liver dysfunction

  5. Preterm neonates

  6. Newborn infants with an indication for exchange transfusion for severe neonatal hyperbilirubinemia

Contacts and Locations

Locations

Site City State Country Postal Code
1 Amsterdam UMC - Emma Children's Hospital Amsterdam Netherlands
2 UMC Groningen Groningen Netherlands
3 UMC Utrecht Utrecht Netherlands

Sponsors and Collaborators

  • Amsterdam University Medical Centers (UMC), Location Academic Medical Center (AMC)
  • Stichting Kinderen Kankervrij (KiKa)

Investigators

  • Principal Investigator: Joep Derikx, MD, PhD, Amsterdam UMC - Emma Children's Hospital

Study Documents (Full-Text)

None provided.

More Information

Additional Information:

Publications

None provided.
Responsible Party:
Daniël van de Berg, MD, MD, Amsterdam University Medical Centers (UMC), Location Academic Medical Center (AMC)
ClinicalTrials.gov Identifier:
NCT05917067
Other Study ID Numbers:
  • 2023.0263
First Posted:
Jun 23, 2023
Last Update Posted:
Jun 23, 2023
Last Verified:
Jun 1, 2023
Individual Participant Data (IPD) Sharing Statement:
Yes
Plan to Share IPD:
Yes
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Daniël van de Berg, MD, MD, Amsterdam University Medical Centers (UMC), Location Academic Medical Center (AMC)
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jun 23, 2023